Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Clin Sci (Lond). 2010 Apr 7;119(1):45-55. doi: 10.1042/CS20090601.
Increasing NO bioavailability improves hepatic endothelial dysfunction, which ameliorates intrahepatic resistance and portal hypertension. Acute administration of sildenafil increases hepatic production of NO with a reduction in hepatic sinusoid resistance in cirrhotic patients and enhances the vasorelaxation response to NO in cirrhotic rat livers. However, the mechanisms were still unclear. Therefore, our present study aims to evaluate the effects and mechanisms of administration of sildenafil for 1 week on the hepatic microcirculation of cirrhotic rats. Cirrhosis was induced by bile duct ligation with sham-operated rats serving as normal controls. Intrahepatic resistance was evaluated by in situ liver perfusion. Expression of phospho-eNOS (endothelial NO synthase), iNOS (inducible NO synthase), phospho-Akt, PDE-5 (phosphodiesterase-5) and sGC (soluble guanylate cyclase) were determined by Western blot analysis. Biosynthesis of BH4 (tetrahydrobiopterin) and GTPCH-I (GTP cyclohydrolase I) activity were examined by HPLC. Intravital microscopy was used to observe the direct change in hepatic microcirculation. In cirrhotic rat livers, sildenafil treatment increased hepatic sinusoid volumetric flow, NO bioavailability, BH4, GTPCH-I activity, and the protein expression of phospho-Akt, phospho-eNOS and sGC. These events were associated with reduced protein expression of PDE-5, portal perfusion pressure and portal vein pressure. In contrast, sham rats did not produce any significant change in these measurements. In conclusion, sildenafil treatment improves endothelial dysfunction by augmenting NO bioavailability in the hepatic microcirculation.
增加 NO 的生物利用度可改善肝内皮功能障碍,从而减轻肝内阻力和门静脉高压。在肝硬化患者中,急性给予西地那非可增加肝内 NO 的产生,减少肝窦阻力,并增强肝硬化大鼠肝脏对 NO 的血管舒张反应。然而,其机制仍不清楚。因此,本研究旨在评估西地那非治疗 1 周对肝硬化大鼠肝微循环的影响及其机制。通过胆管结扎诱导肝硬化,假手术大鼠作为正常对照。通过原位肝灌注评估肝内阻力。通过 Western blot 分析测定磷酸化 eNOS(内皮型一氧化氮合酶)、iNOS(诱导型一氧化氮合酶)、磷酸化 Akt、PDE-5(磷酸二酯酶-5)和 sGC(可溶性鸟苷酸环化酶)的表达。通过 HPLC 检测 BH4(四氢生物蝶呤)和 GTPCH-I(GTP 环水解酶 I)的生物合成。使用活体显微镜观察肝微循环的直接变化。在肝硬化大鼠肝脏中,西地那非治疗可增加肝窦容积流量、NO 生物利用度、BH4、GTPCH-I 活性以及磷酸化 Akt、磷酸化 eNOS 和 sGC 的蛋白表达。这些变化与 PDE-5 蛋白表达降低、门静脉灌注压和门静脉压降低有关。相比之下,假手术大鼠在这些测量中没有产生任何显著变化。总之,西地那非治疗通过增加肝内微循环中 NO 的生物利用度改善内皮功能障碍。